SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Persson Jenny L.) "

Sökning: WFRF:(Persson Jenny L.)

  • Resultat 1-10 av 63
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Fredholm, Simon, et al. (författare)
  • SATB1 in Malignant T Cells
  • 2018
  • Ingår i: Journal of Investigative Dermatology. - Nature Publishing Group. - 0022-202X.
  • Tidskriftsartikel (refereegranskat)abstract
    • Deficient expression of SATB1 hampers thymocyte development and results in inept T-cell lineages. Recent data implicate dysregulated SATB1 expression in the pathogenesis of mycosis fungoides, the most frequent variant of cutaneous T-cell lymphoma. Here, we report on a disease stage-associated decrease of SATB1 expression and an inverse expression of STAT5 and SATB1 in situ. STAT5 inhibited SATB1 expression through induction of microRNA-155. Decreased SATB1 expression triggered enhanced expression of IL-5 and IL-9 (but not IL-6 and IL-32), whereas increased SATB1 expression had the opposite effect, indicating that the microRNA-155 target SATB1 is a repressor of IL-5 and IL-9 in malignant T cells. In accordance, inhibition of STAT5 and its upstream activator JAK3 triggered increased SATB1 expression and a concomitant suppression of IL-5 and IL-9 expression in malignant T cells. In conclusion, we provide a mechanistic link between the proto-oncogenic JAK3/STAT5/microRNA-155 pathway, SATB1, and cytokines linked to CTCL severity and progression, indicating that SATB1 dysregulation is involved in cutaneous T-cell lymphoma pathogenesis.
  •  
2.
  • Fridberg, Marie, et al. (författare)
  • Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: Higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN
  • 2007
  • Ingår i: Leukemia Lymphoma. - InformaWorld. - 1042-8194. ; 48:11, s. 2221-32
  • Tidskriftsartikel (refereegranskat)abstract
    • Patients diagnosed with diffuse large B-cell lymphoma (DLBCL) show varying responses to conventional therapy, and this might be contributed to the differentiation stage of the tumor B-cells. The aim of the current study was to evaluate a panel of kinases (ZAP70, PKC-beta I and II and phosphorylated PKB/Akt) and phosphatases (PTEN, SHP1 and SHP2) known to be frequently deregulated in lymphoid malignancies. De novo DLBCL cases were divided into two subgroups, the germinal center (GC) group (14/28) and the non-germinal center (non-GC) or activated B-cell (ABC) group (14/28). ZAP70 and PKC-beta II were expressed in a significantly higher percentage of tumor cells in the clinically more aggressive non-GC group compared with the prognostically favourable GC group. Also, the subcellular localization of PKC-beta I and II differed in DLBCL cells, with the PKC-beta I isoform being expressed in both the cytoplasm and nucleus, while PKC-beta II was found exclusively in the cytoplasm. Loss of nuclear PTEN correlated with poor survival in cases from both subgroups. In addition, five cell lines of DLBCL origin were analyzed for protein expression and for mRNA levels of PTEN and SHP1. For the first time, we show that ZAP70 is expressed in a higher percentage of tumor cells in the aggressive non-GC subgroup of DLBCL and that PKC-beta I and II are differently distributed in the two prognostic subgroups of de novo DLBCL.
3.
  • Stanezai, S., et al. (författare)
  • Higher intensity of Low Molecular Weight Protein Tyrosine Phosphatase/ ACP-1 in survivors of patients diagnosed with Diffuse Large B Cell Lymphoma (DLBCL) compared to non-survivors
  • 2016
  • Ingår i: Austin Biology. ; :2
  • Tidskriftsartikel (refereegranskat)abstract
    • Adult Diffuse Large B Cell Lymphoma (DLBCL) is a heterogeneous form of hematopoietic cancer and difficult to treat. In order to find a better diagnostic indication for the disease, we analyzed Low Molecular Weight Protein Tyrosine Phosphatase (LMWPTP) that in humans is encoded by the ACP1 gene. LMWPTP is an enzyme shown to counteract Protein Tyrosine Kinases (PTK) and was suggested to be a negative growth factor regulator. However, the 18 kDa PTP can also have a positive effect on cell growth and proliferation, indicating a controversial role in the tumorigenic process. LMWPTP exists in different isoforms which are electrophoretically, kinetically and immunologically distinct. We have studied two subgroups of DLBCL consisting of a Germinal Center B cell like (GCB) and a non-Germinal Center B cell like (non-GCB) group. The two subgroups have been defined by gene-expressing profiling and are associated with differential outcome. The expression levels of LMWPTP protein was compared and showed significant differences between the GCB and non- GCB subgroups (p=0.012). Interestingly, when the samples were divided into survivors and non-survivors, and thereafter analyzed for LMWPTP expression, the samples from patients with a higher survival rate showed increased staining intensity, whereas the samples from patients with lower intensity of LMWPTP did not survive the disease (p=0.001). In conclusion, we have shown that DLBCL patients with worse outcome express LMWPTP with a lower intensity, suggesting a tumor suppressor role for this form of the enzyme.
4.
  • Fridberg, Marie, et al. (författare)
  • Immunohistochemical analyses of phosphatases in childhood B-cell lymphoma: lower expression of PTEN and HePTP and higher number of positive cells for nuclear SHP2 in B-cell lymphoma cases compared to controls.
  • 2008
  • Ingår i: Pediatric Hematology & Oncology. - Hemisphere Pub. Corp.. - 1521-0669. ; 25:6, s. 528-540
  • Tidskriftsartikel (refereegranskat)abstract
    • Although many pediatric B-cell lymphoma patients are being cured today, much is still unknown about the pathogenesis of this disease. Protein tyrosine phosphatases are involved in the control of survival, growth, and differentiation of cells. The authors have analyzed 26 pediatric B-cell lymphoma cases for the expression of a panel of phosphatases and report a statistically significant lower expression intensity of PTEN and HePTP and higher nuclear SHP2 expression in B-cell lymphoma cases compared to lymphoid tissue. Knowledge about the expression of key regulatory proteins in pediatric B-cell lymphomas is necessary for revealing the complex molecular background of this disease.
5.
  • Diffner, E, et al. (författare)
  • Expression of VEGF and VEGF Receptors in Childhood Precursor B-cell Acute Lymphoblastic Leukemia Evaluated by Immunohistochemistry.
  • 2009
  • Ingår i: Journal of Pediatric Hematology/Oncology1995-01-01+01:00. - Lippincott Williams & Wilkins. - 1536-3678. ; 31, s. 696-701
  • Tidskriftsartikel (refereegranskat)abstract
    • Perturbation in the expression and signaling pathways of vascular endothelial growth factor (VEGF) has been linked to pathogenesis of hematologic malignancies. We investigated the expression and clinical importance of VEGF and two of its receptors, VEGFR-1 and VEGFR-2, in childhood precursor B-cell acute lymphoblastic leukemia (pre-B ALL) by using immunohistochemistry. These angiogenic proteins were expressed in the majority of leukemic bone marrow samples. Notably, pre-B ALL patients had significantly increased expression of VEGFR-1 compared with no expression in the nonmalignant group, indicating a link between VEGFR-1 protein expression and pre-B ALL. These novel findings suggest that VEGFR-1 may have clinical importance in childhood pre-B ALL.
  •  
6.
  •  
7.
8.
  • Ekberg, Jenny, et al. (författare)
  • Post-translational modification of cyclin A1 is associated with staurosporine and TNFalpha induced apoptosis in leukemic cells.
  • 2009
  • Ingår i: Molecular and Cellular Biochemistry. - Springer. - 0300-8177. ; 320:1-2, s. 115-124
  • Tidskriftsartikel (refereegranskat)abstract
    • Understanding of molecular mechanisms underlying the effects of cell cycle proteins in response to the chemotherapeutic agents is of great importance for improving the efficacy of targeted therapeutics and overcoming resistance to chemotherapeutic agents. Staurosporine and tumor necrosis factor alpha (TNFalpha) are the therapeutic agents that inhibit tumor cell growth by inducing cell death. Staurosporine induces apoptosis through the intrinsic pathway, while TNFalpha trigger the cell death via the extrinsic apoptotic pathway. We have previously demonstrated that the cell cycle regulatory protein, cyclin A1 played an important role in the development of acute myeloid leukemia (AML), and cyclin A1 expression correlated with disease characteristics and patient outcome in leukemia. However, it remains unknown how cyclin A1 expression is regulated in leukemic cells treated with the therapeutic agents. Here, we demonstrate that cyclin A1 protein is regulated by proteasome-mediated ubiquitination and degradation in untreated U-937 cells. Interestingly, ubiquitination- and proteasomal-mediated degradation of cyclin A1 is prevented in cells treated with staurosporine or TNFalpha. Induction of apoptosis in U-937 cells by staurosporine or TNFalpha resulted in an increase in cyclin A1 protein expression, which correlated well with cyclin A1 protein modification and the activation of caspase-3. Blocking caspases activity by Z-VAD-FMK had no effect on the increased cyclin A1 expression, suggesting that cyclin A1 might be regulated by caspase-3 independent pathways. We further propose that CDC25C may be associated with cyclin A1 protein modification in response to staurosporine or TNFalpha treatment. Our results suggest that cyclin A1 protein is stabilized via post-transcriptional modification in response to apoptosis induced by staurosporine or TNFalpha.
  •  
9.
10.
  • Larsson, Rikard, et al. (författare)
  • Clinical Trial Update and Novel Therapeutic Approaches for Metastatic Prostate Cancer.
  • 2011
  • Ingår i: Current Medicinal Chemistry. - Bentham Science Publishers. - 0929-8673. ; 18, s. 4440-4453
  • Tidskriftsartikel (refereegranskat)abstract
    • Recurrent prostate cancer (PCa) remains a major clinical challenge. Invasive and metastatic PCa lesions often exhibit a partial and time-limited response to therapy before the cancer progresses and the patient succumbs to the disease. Despite recent advances in early diagnosis and treatment, approximately one-third of treated patients will relapse and become resistant to currently available treatments. In this review we evaluate current treatment practices and recent advances in therapy for localized prostate malignancy and advanced, metastatic prostate cancer. Some of the promising new drugs for PCa treatment include MDV3100, an androgen receptor (AR) antagonist that prevents androgens from binding to the AR and nuclear translocation and co-activator recruitment of the ligand-receptor complex; abiraterone, an orally administered drug that irreversibly inhibits a rate-limiting enzyme in androgen biosynthesis, CYP17; and several newer cytotoxic drugs (epothilones, satraplatin). Key new insights are that cancer stem cells play a role in PCa and that PCa cells are dependent on the AR for proliferation, even in the hormone refractory state of the disease. We also discuss potential molecular targets for new drug candidates for the treatment of metastatic PCa.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 63
Åtkomst
fritt online (26)
Typ av publikation
tidskriftsartikel (56)
forskningsöversikt (5)
konferensbidrag (2)
Typ av innehåll
refereegranskat (62)
övrigt vetenskapligt (1)
Författare/redaktör
Persson, Jenny L., (57)
Mongan, Nigel P., (13)
Miftakhova, Regina, (8)
Dizeyi, Nishtman, (6)
Bjartell, Anders, (6)
Gjörloff Wingren, An ... (6)
visa fler...
Anagnostaki, Lola (6)
Ødum, Niels, (6)
Abrahamsson, Per-And ... (5)
Härkönen, Pirkko, (5)
Heery, David M, (5)
Odum, Niels (5)
Helczynski, Leszek, (5)
Allegrucci, Cinzia (5)
Landberg, Göran (4)
Robinson, Brian D., (4)
Willerslev-Olsen, An ... (4)
Fredholm, Simon (4)
Nastasi, Claudia (4)
Geisler, Carsten (4)
Woetmann, Anders (4)
Wigerup, Caroline, (3)
Johansson, Martin (3)
Blümel, Edda, (3)
Bredberg, Anders, (3)
Brunhoff, Cecilia, (3)
Gluud, Maria (3)
Hu, Tengpeng (3)
Lindahl, Lise M. (3)
Iversen, Lars (3)
Tinzl, Martina, (3)
Shcherbina, Liliya, (2)
Sterner, Olov, (2)
Larsson, Per, (2)
Rosén, Anders, (2)
Sasseville, Denis (2)
Mustelin, Tomas (2)
Larsson, Rikard, (2)
Richter, Johan (2)
Metzler, Veronika M. ... (2)
Rutland, Catrin S., (2)
Jeyapalan, Jennie N. ... (2)
Sjölander, Anita, (2)
Fridberg, Marie (2)
Anagnostaki, L. (2)
Nilsson, Elise, (2)
Zhang, Yuan (2)
Litvinov, Ivan V. (2)
Sandberg, Tove (2)
de Brot, Simone (2)
visa färre...
Lärosäte
Lunds universitet (58)
Umeå universitet (11)
Malmö universitet (7)
Högskolan Kristianstad (2)
Uppsala universitet (2)
Linköpings universitet (2)
visa fler...
Karolinska Institutet (2)
Göteborgs universitet (1)
Chalmers tekniska högskola (1)
Karlstads universitet (1)
visa färre...
Språk
Engelska (63)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (58)
Naturvetenskap (4)
Lantbruksvetenskap (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy